A gastroenteropancreatic neuroendocrine tumor (GEP-NET) is a rare type of tumor that can grow in the pancreas or other areas of the gut, such as the stomach, small intestine,...

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are relatively rare and complex neoplasms that present many clinical challenges. Most GEP-NETs are sporadic, but they can be multiple and a component of a familial syndrome.

Apr 6, 2020 · Gastroenteropancreatic NENs (GEP-NENs) constitute a heterogeneous group of malignancies with a neuronal phenotype and the capacity to secrete amines and hormones. They share similarities with neuroendocrine cells of the embryological gut.

GEP-NETs are NETs that grow in the gastrointestinal tract, including the stomach, small intestine, rectum, colon, and appendix, or in the pancreas. What are the signs and symptoms of GEP-NETs? GEP-NET symptoms vary, depending on the specific type.

May 4, 2020 · This article summarizes key data and discussion points from this scientific interchange, including current GEP-NET therapies—such as somatostatin analogues (SSAs), peptide receptor radionuclide...

A rare type of tumor that can form in the pancreas or in other parts of the gastrointestinal tract, including the stomach, small intestine, colon, rectum, and appendix. GEP-NETs usually form in cells that secrete hormones.

Gastroenteropancreatic neuroendocrine tumors (GEP-NET) are slow-growing neoplasms that arise from the neuroendocrine system of the gastrointestinal tract and pancreas. These may be classified based on location into the following: pheochromocytomas and parangangliomas; carcinoids; and pancreatic endocrine tumors.

If you’ve been diagnosed with a gastroenteropancreatic neuroendocrine tumor (GEP-NET), we’re here to help. It’s possible and understandable that you feel anxious or tense, but by navigating through this website you can obtain valuable information about …

GEP-NETs are neuroendocrine tumors that originate in the GI tract. About 60% of GEP-NETs are nonsecretory or secretory without clinical manifestations; they may be detected incidentally or may present with weight loss, abdominal pain, or jaundice.

Detection of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and monitoring of treatment response relies mainly on morphological imaging such as computed tomography (CT) and magnetic resonance imaging (MRI).